Stockscreener 앱 받기
0.75
40.45%
0.216
Brainstorm Cell Therapeutics Inc 주식(BCLI)의 최신 뉴스
BrainStorm adds ex-FDA official to board ahead of ALS trial - Investing.com Australia
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors - PR Newswire
7.8M Brainstorm (OTCQB: BCLI) shares registered for warrant-linked resale - Stock Titan
BrainStorm Cell (BCLI) director receives 150,000 stock options at $0.70 strike - Stock Titan
BrainStorm Cell (BCLI) director granted 150K options at $0.70 strike - Stock Titan
BRAINSTORM CELL (BCLI) director receives 225,000 stock options at $0.70 strike - Stock Titan
Brainstorm Cell (BCLI) director receives grant of 150,000 stock options at $0.70 - Stock Titan
BrainStorm Cell (BCLI) grants director Naor Nir 180K stock options - Stock Titan
[Form 4] BRAINSTORM CELL THERAPEUTICS INC. Insider Trading Activity - Stock Titan
BrainStorm raises $400,000 in May private placement at premium By Investing.com - Investing.com South Africa
BrainStorm raises $400,000 in May private placement at premium - Investing.com
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market - StreetInsider
Press Release: BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market - Moomoo
BrainStorm reports Q1 2026 loss but advances Phase 3 trial for ALS treatment NurOwn. - Pluang
BrainStorm Cell Therapeutics posts $2.1M quarterly net loss, cash ~$0.2M as of Mar 31, 2026 - TradingView
BrainStorm Cell (OTCQB: BCLI) posts Q1 2026 loss and details NurOwn ALS plans - Stock Titan
Brainstorm Cell Therapeutics announces first quarter 2026 financial results and provides corporate update - marketscreener.com
Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update - TradingView
BRAINSTORM CELL THERAPEUTICS INC. 1Q 2026: Net income $(2.13M), EPS $(0.19) — 10-Q Summary - TradingView
Brainstorm Cell (BCLI) Q1 2026 loss deepens going-concern pressures - Stock Titan
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Brainstorm Cell Therapeutics (BCLI) Eps Diluted (TTM) - Zacks Investment Research
MSN Money - MSN
Brainstorm Cell Therapeutics Inc. announced that it has received $0.2 million in funding - marketscreener.com
Brainstorm Cell Therapeutics Inc. announced that it expects to receive $0.2 million in funding - marketscreener.com
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Quantisnow
BCLI SEC FilingsBrainstorm Cell Therapeutics I 10-K, 10-Q, 8-K Forms - Stock Titan
Top Synthetic Stem Cells MarketAthersys, Inc., BrainStorm - openPR.com
Leading Companies Reinforcing Their Presence in the Stem Cell Therapy for Multiple Sclerosis Market - openPR.com
Aug Shorts: What is the target price for Brainstorm Cell Therapeutics Inc stockMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Layoff Watch: Whats the profit margin of Brainstorm Cell Therapeutics IncGold Moves & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Brainstorm Cell Therapeutics Inc. (BCLI) Stock Price | Live Quotes & Charts | OTCQB - StocksToTrade
Brainstorm Cell Therapeutics 2025 10-K: $0.0M Revenue, $(1.11) EPS - TradingView — Track All Markets
ALS therapy pivot: BrainStorm (BCLI) pulls BLA, wins FDA SPA for new Phase 3b - Stock Titan
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BrainStorm Cell (OTCQB: BCLI) posts 2025 loss, tight cash and equity deficit - Stock Titan
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update - ChartMill
Growth Value: What is the target price for Brainstorm Cell Therapeutics Inc stock2026 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
Gap Down: Whats the profit margin of Brainstorm Cell Therapeutics Inc2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Pullback Watch: Is Brainstorm Cell Therapeutics Inc in a long term uptrend2026 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Breakout Zone: Does Brainstorm Cell Therapeutics Inc have declining or rising EPS2026 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® - Nasdaq
If You Invested $1,000 in Brainstorm Cell Therapeutics I (BCLI) - Stock Titan
Tech Rally: Is Brainstorm Cell Therapeutics Inc stock risky to hold nowEarnings Performance Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 Delveinsight Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - menafn.com
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Insider Buy: Is Olema Pharmaceuticals Inc forming bullish engulfing patterns2026 Short Interest & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Weekly Recap: How do insiders feel about Brainstorm Cell Therapeutics Inc2026 Short Interest & Community Trade Idea Sharing - baoquankhu1.vn
Maxim Group downgrades Brainstorm Cell Therapeutics (BCLI) - MSN
S P Trends: Is Brainstorm Cell Therapeutics Inc in a long term uptrend2025 Top Gainers & Weekly Breakout Watchlists - baoquankhu1.vn
BCLI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Brainstorm Cell Therapeutics Adds Shares to Equity Incentive Plan - TipRanks
Brainstorm Cell Therapeutics Arranges Up to $1.0 Million Private Placement at $0.60, Adds Warrants - TradingView
Brainstorm Cell (BCLI) launches $1M private placement and adds 5.5M incentive shares - Stock Titan
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - GuruFocus
Brainstorm Cell secures second $1M private placement this month By Investing.com - Investing.com Nigeria
Brainstorm Cell secures second $1M private placement this month - Investing.com
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February - Nasdaq
Aug Outlook: Whats the profit margin of Brainstorm Cell Therapeutics IncPortfolio Update Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
0.27%
0.14%
자본화:
|
볼륨(24시간):